Driving results for early stage med-tech and life sciences companies through experience and strategic execution.

ABOUT

2409 Advisors provides fractional leadership and advisory services to help early-stage Med-Tech and Life Sciences companies secure capital, navigate regulatory requirements, improve operational efficiency, and execute commercial launch strategies that drive measurable growth.

TEAM

Chris Mathia is the founder of 2409 Advisors and an experienced healthcare executive having held leadership roles with organizations such as Cerner Corporation, Hyland Software, Thomson Reuters, B. Braun, and Medline Industries.

Most recently, Chris served as CEO of Innara Health. During his tenure, he successfully led the company through a comprehensive reorganization, secured funding, and achieved consistent year-over-year revenue growth. Additionally, he oversaw the development, regulatory re-submission, and commercial launch of the fully redesigned 510(k) cleared NTrainer 2.0, which led to the company’s acquisition by Cardinal Health in early 2023.

With a passion for pediatrics, Chris specializes in commercialization and go-to-market strategies for early-stage medical device and life science companies.

He is an alumnus of the MedTech Innovator 2020 Pediatric Cohort and a $50K non-dilutive grant winner from the Children’s National “Make Your Pitch for Kids” pitch competition. Chris holds a bachelor’s degree in Political Science from the University of Kansas.

Chris Mathia

Current Projects

  • Fractional CRO/CMO supporting capital raise activities while developing commercial launch and reimbursement strategy for early-stage company focused on Maternal & Children’s health.

  • Entrepreneur in Residence for nationally recognized innovation intermediary focused on providing comprehensive advisory services and support for early-stage, NIH, BARDA, and ARPA-H funded organizations.

  • Commercialization advisor for pre-FDA medical device company focusing on Respiratory Health.

  • Advisor for venture firm with interests in expanding portfolio to include Life Sciences and Healthcare Technology companies.

Stay in the know

Occasionally, we’ll release a newsletter or an update highlighting our client’s success. Feel free to sign up for a “no-solicit” update.